Carfilzomib for the Prevention of Graft Versus Host Disease

Status Recruiting

Clinical Trial Summary

The aim of this study is to evaluate the safety and efficacy of Carfilzumib, which is a novel biological agent used in the treatment of multiple myeloma in preventing graft-versus-host disease, after stem cells transplantation from unrelated donors.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01991301
Study type	Interventional
Source	Sheba Medical Center
Contact	Arnon Nagler, MD
Phone	972 3 530 5830
Email	a.nagler@sheba.health.gov.il
Status	Recruiting
Phase	Phase 1
Start date	November 2014
Completion date	November 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01428973` - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens	Phase 2
Not yet recruiting	`NCT00749164` - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment	Phase 1/Phase 2
Completed	`NCT00993343` - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation	Phase 3
Completed	`NCT00360685` - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX	N/A
Active, not recruiting	`NCT04503616` - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention	Phase 1/Phase 2
Terminated	`NCT02080195` - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)	Phase 1/Phase 2
Completed	`NCT02193880` - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)	N/A
Completed	`NCT02942173` - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT01941394` - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation	Phase 2
Completed	`NCT00141713` - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease	Phase 2
Completed	`NCT00408928` - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease	Phase 2
Completed	`NCT01633229` - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications	Phase 1
Completed	`NCT05856058` - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability	Phase 1
Completed	`NCT02342613` - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT06423131` - Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT	N/A
Completed	`NCT02144025` - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT	Phase 2
Completed	`NCT01369914` - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed	`NCT00806728` - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease	Phase 1
Completed	`NCT01851382` - Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research